Nanobiotix announces a license agreement with Janssen Pharmaceutica for worldwide co-development and commercialization of potential first-in-class radioenhancer NBTX R3.
Nanobiotix a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced a global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the investigational, potential first-in-class radioenhancer NBTX R3.
NBTX R3 is currently being evaluated in several studies across solid tumor indications including NANORAY-312, a global Phase III pivotal study evaluating NBTX R3 for the treatment of patients with locally advanced head and neck cancer. NBTX R3 is also being evaluated for its potential as a systemic agent in combination with anti-PD-1 immune checkpoint inhibitors for patients with metastatic cancers.
Under the terms of the license agreement, in collaboration with the Interventional Oncology R&D Unit at Johnson & Johnson, Nanobiotix will grant Janssen a worldwide license for the development and commercialization of NBTX R3. The license is exclusive, excepting territories previously licensed to Nanobiotix partner LianBio.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins